• PDF: Delivered by email usually within 48 UK business hours.

Alnylam Pharmaceuticals, Inc (ALNY) - Pharmaceuticals & Healthcare
Deals and Alliances Profile

  • Publication Date:March 2012
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:246

Alnylam Pharmaceuticals, Inc (ALNY) - Pharmaceuticals & Healthcare Deals and Alliances Profile

Summary

Alnylam Pharmaceuticals, Inc., (Alnylam Pharmaceuticals) is a biopharmaceutical company engaged in the development of therapeutics based on ribonucleic acid interference (RNAi). The product portfolio of the company comprises a range of ALN-RSV01 (Respiratory Syncytial Virus Infection), ALN-VSP (Liver Cancers), ALN-PCS (PCSK9/Hypercholesterolemia), ALN-TTR (TTR Amyloidosis), ALN-HTT (Huntington's Disease), ALN-HPN (Refractory Anemia) and ALN-RSV(Respiratory Syncytial Virus). The company's lead RNAi therapeutic program, ALN-RSV01, for the treatment of human respiratory syncytial virus (RSV) infection is in Phase II clinical trials. The company also develops a product for liver cancer in phase I and three more products in preclinical trials. In addition, the company is also engaged in preclinical programs. Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals, Inc (ALNY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals and Healthcare eTrack deals database, and primary and secondary research.

Scope

  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

  • Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare Deals By Type, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Medical Devices Deals, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals Summary, 2006 to YTD 2012
  • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deal Details
  • Asset Purchase
  • Alnylam Acquires RNAi Therapeutics Assets From Nucleonics
  • Venture Financing
  • Regulus Therapeutics Secures $20 Million In Series A Preferred Equity Financing
  • Partnerships
  • Molecular Templates Enters Into Research Collaboration With Alnylam Pharmaceuticals
  • Precision NanoSystems Enters Into Delivery Collaboration With Alnylam
  • AlCana Extends Co-Development Agreement With UBC And Alnylam
  • Alnylam And Medtronic Form Collaboration With CHDI Foundation
  • Alnylam Pharmaceuticals Enters Into Agreement With Tekmira Pharmaceuticals
  • Novartis Extends Agreement With Alnylam Pharmaceuticals
  • Cubist Pharmaceuticals Enters Into Co-Development Agreement With Alnylam
  • Alnylam Enters Into Research Agreement With Max Planck Institute
  • Novartis Extends Co-Development Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals And Kyowa Hakko Form Alliance
  • Alnylam Pharmaceuticals Forms Joint Venture With Isis Pharmaceuticals
  • Alnylam Pharmaceuticals Amends Agreement With Medtronic
  • Biogen Idec Enters Into Agreement With Alnylam
  • Tekmira Amends Research Collaboration With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals Amends Its Collaboration Agreement With Merck
  • Alnylam Pharmaceuticals Enters Into Collaboration Agreement With USAMRIID
  • Alnylam Pharmaceuticals Enters Into Research Agreement With Inex Pharmaceuticals
  • Alnylam Enters Into Co-Development Agreement With Novartis
  • Licensing Agreements
  • Bio-Rad Laboratories Enters Into An Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Inex Pharmaceuticals
  • Alnylam Enters Into Licensing Agreement With Dharmacon
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Arrowhead Research
  • Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Option Licensing Agreement With Sylentis
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With GlaxoSmithKline
  • Tekmira Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Tekmira Pharmaceutical
  • The University of Queensland Enters Into Licensing Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Mount Sinai School
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With University of Queensland
  • Roche Expands Licensing Agreement With Alnylam
  • Alnylam Enters Into License Agreement With Koken
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Isis Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Calando Pharmaceuticals
  • Takeda Pharmaceutical Enters Into Collaboration Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals And Tekmira Pharmaceutical Enter Into Licensing Agreement
  • Alnylam Enters Into Agreement With Shanghai GenePharma
  • Alnylam Pharmaceuticals Enter Into Licensing Agreement With GeneDesign
  • Roche Enters Into Licensing Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement with Hayashi Kasei
  • Alnylam Enters Into Licensing Agreement With Inex Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Quark Pharmaceuticals
  • Alnylam Enters Into Agreement With Calando
  • Alnylam Enters Into Agreement With Bioneer
  • Alnylam Enters Into Agreement With Immune Disease Institute
  • Alnylam Enters Into Agreements With Massachusetts Institute of Technology
  • Gen-Probe Enters Into Licensing Agreement With Alnylam Pharmaceuticals
  • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Integrated DNA Technologies
  • Equity Offering
  • Alnylam Pharmaceuticals Files Registration Statement For Public Offering Of Securities For $150 Million
  • Alnylam Completes Private Placement Of $1 Million With Novartis
  • Tekmira Completes Private Placement Of $5 Million With Alnylam
  • Alnylam Pharmaceuticals Completes Private Placement Of $5 Million
  • Alnylam Pharmaceuticals Completes Public Offering Of $103 Million
  • Alnylam Completes Public Offering Of $67 Million
  • Alnylam Pharmaceuticals, Inc - Key Competitors
  • Key Employees
  • Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
    • Strategy And Business Planning
    • Jan 08, 2012: Alnylam Provides Key 2012 Goals For RNAi Therapeutics Pipeline
    • Sep 23, 2010: Alnylam Provides Update On Novartis Collaboration, Announces Corporate Restructuring, And Reaffirms Financial Guidance For 2010
    • Aug 05, 2010: Alnylam Scientists Contribute To Discovery Of New Disease Gene In Cardiovascular Disease
    • Nov 04, 2009: Alnylam Advances RNAi Therapeutic Collaboration With Roche
    • Nov 04, 2009: Alnylam, Roche Advance RNAi Therapeutic Collaboration Stage
    • Aug 06, 2009: Alnylam, Tekmira Participate In New Research Collaboration
    • Jul 20, 2009: Alnylam, Cubist Provide Complete Data On Phase II Study Of ALN-RSV01
    • Jul 17, 2009: Novartis Extends Alnylam's RNAi Therapeutics Collaboration
    • Jun 08, 2009: Alnylam, Cubist Reports Preliminary Data From Phase II Study Of ALN-RSV01
    • Jan 09, 2009: Alnylam And Cubist Partner To Develop And Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus Infection
    • Financial Announcements
    • Nov 01, 2011: Alnylam Pharmaceuticals Reports Revenue Of $20.8m In Q3 2011
    • Aug 01, 2011: Alnylam Pharmaceuticals Reports Net Revenue Of $20.6m For Q2 2011
    • May 02, 2011: Alnylam Pharmaceuticals Reports Net Loss Of $16.3m For Q1 2011
    • Feb 17, 2011: Alnylam Pharmaceuticals Reports Net Loss Of $6.9m In Q4 2010
    • Nov 03, 2010: Alnylam Reports Net Loss Of $9.6 Million For Q3 2010
    • Nov 03, 2010: Alnylam Reports Net Loss Of $9.6 Million For Q3 2010
    • Aug 04, 2010: Alnylam Reports Net Loss Of $14.6 Million For Q2 2010
    • May 05, 2010: Alnylam Pharmaceuticals Reports Net Loss Of $12.3 Million For Q1 2010
    • Feb 25, 2010: Alnylam Pharmaceuticals Reports Net Loss Of $7.7 In Q4 2009
    • Nov 04, 2009: Alnylam Q3 2009 Net Loss Increases
    • Nov 04, 2009: Alnylam Reports Net Loss Of $9.2 Million For Q3 2009
    • Aug 06, 2009: Alnylam Q2 2009 Net Loss Increases
    • Aug 06, 2009: Alnylam Reports Net Loss Of $22.7 Million For Q2 2009
    • May 07, 2009: Alnylam Q1 2009 Net Loss Increases
    • May 07, 2009: Alnylam Reports Net Loss Of $7.9 Million For Q1 2009
    • Feb 24, 2009: Alnylam Reports Net Loss Of $9.4 Million In Q4 2008
    • Nov 05, 2008: Alnylam Pharmaceuticals Reports Third Quarter 2008 Financial Results
    • Aug 06, 2008: Alnylam Pharmaceuticals Reports Second Quarter 2008 Financial Results
    • May 08, 2008: Alnylam Pharmaceuticals Reports First Quarter 2008 Financial Results
    • Feb 07, 2008: Alnylam Pharmaceuticals Reports Fourth Quarter And 2007 Financial Results
    • Nov 01, 2007: Alnylam Pharmaceuticals Reports Third Quarter 2007 Financial Results
    • Aug 09, 2007: Alnylam Pharmaceuticals Reports Second Quarter 2007 Financial Results
    • May 09, 2007: Alnylam Pharmaceuticals Reports First Quarter 2007 Financial Results
    • May 02, 2007: Alnylam To Webcast Conference Call Discussing First Quarter 2007 Financial Results
    • Feb 07, 2007: Alnylam Pharmaceuticals Reports Fourth Quarter And 2006 Financial Results
    • Nov 02, 2006: Alnylam Pharmaceuticals Reports Third Quarter 2006 Financial Results
    • Jul 26, 2006: Alnylam Pharmaceuticals Reports Second Quarter 2006 Financial Results; Increasing Revenue Drives Improvement In Year-Over-Year Financials
    • May 09, 2006: Alnylam Pharmaceuticals Reports First Quarter 2006 Financial Results; Company Achieves Multiple Milestones And Recognizes Increased Revenue From Pharmaceutical Partners
    • Feb 15, 2006: Alnylam Pharmaceuticals Reports Fourth Quarter And Year End 2005 Financial Results
    • Nov 09, 2005: Alnylam Pharmaceuticals Reports Third Quarter 2005 Financial Results; Company Continues Leadership With Products, Partnerships, Technology, And Intellectual Property For Rnai Therapeutics
    • Aug 03, 2005: Alnylam Pharmaceuricals Reports Second Quarter 2005 Financial Results; Continued Progress In Rnai Therapeutic Development Efforts; Realizing Value From Leading Intellectual Property Estate In Rnai
    • May 11, 2005: Alnylam Pharmaceuticals Reports First Quarter 2005 Financial Results; Advanced And Expanded Rnai Therapeutic Pipeline; Continued To Build World-Leading Ip Estate; Strengthened Development Capabilities With Strategic Alliances
    • Feb 15, 2005: Alnylam Pharmaceuticals Reports 2004 Financial Results; Solid Financial Position Supports Continued Development For Rnai Therapeutics
    • Nov 10, 2004: Alnylam Pharmaceuticals Reports Third Quarter 2004 Financial Results
    • Aug 04, 2004: Alnylam Pharmaceuticals Reports Second Quarter 2004 Financial Results
    • Research And Development
    • Jul 19, 2011: Alnylam And MIT Collaborators Publish Data On New Lipid Nanoparticles For Systemic Delivery Of RNAi Therapeutics
    • Apr 07, 2011: AlCana Technologies, The University Of British Columbia And Alnylam Extend Delivery Research Collaboration
    • Nov 04, 2010: Alnylam Grants InterfeRxTM Intellectual Property License To Tekmira
    • Nov 03, 2010: Alnylam, Medtronic And CHDI Foundation Form Collaboration To Advance RNAi Therapeutics For Treatment Of Huntington's Disease
    • Aug 16, 2010: MMV To Contribute Patents To Pool For Open Innovation Against Neglected Tropical Diseases
    • Aug 06, 2009: Alnylam Forms New Research Collaboration With Tekmira
    • Apr 29, 2009: Isis And Alnylam Partner To Develop Single-Stranded RNAi Technology
    • Corporate Communications
    • Jun 13, 2011: Alnylam Appoints Akshay Vaishnaw As Chief Medical Officer
    • Jun 07, 2011: Alnylam Provides Organizational Update
    • Mar 03, 2011: Alnylam Pharmaceuticals Promotes Michael Mason To Vice President, Finance And Treasurer
    • Dec 09, 2010: Alnylam Appoints Marsha Fanucci To Board
    • Sep 22, 2010: Alnylam Elects Steven Paul As New Board Member
    • Jun 02, 2010: Alnylam Announces Senior Management Changes
    • Jan 27, 2009: Alnylam Promotes Akshay Vaishnaw To Senior Vice President, Clinical Research
    • Legal and Regulatory
    • Jan 17, 2012: Alnylam Files Patent Infringement Suit Against Tekmira
    • Jan 17, 2012: Tekmira Provides Periodic Update On Litigation Against Alnylam
    • Dec 21, 2011: Tekmira Provides Update On Litigation Against Alnylam And AlCana
    • Oct 20, 2011: Tekmira Provides Periodic Update to Litigation
    • Jun 29, 2011: Alnylam Files Answer And Counterclaim Related To Tekmira Lawsuit
    • Jun 03, 2011: Tekmira Files Amended Complaint In Alnylam Litigation
    • Apr 07, 2011: Tekmira Comments On Answer And Counterclaim Filed By Alnylam
    • Apr 06, 2011: Alnylam Files Answer And Counterclaim Related To Tekmira Lawsuit
    • Mar 17, 2011: Alnylam Responds To Tekmira Complaint
    • Mar 16, 2011: Tekmira Sues Alnylam Pharmaceuticals For Repeated Misuse Of Trade Secrets And Confidential Information
    • Mar 15, 2011: Alnylam Pharmaceuticals Reaches Settlement In Litigation Regarding Tuschl Patents
    • Dec 02, 2010: Alnylam's Tuschl II Patent Fully Upheld In European Opposition Proceedings
    • Mar 02, 2010: Alnylam Provides Update On Ongoing Litigation Regarding Tuschl I Patent Series
    • Government and Public Interest
    • Oct 20, 2011: Alnylam To Present At Newsmakers In Biotech Industry 2011 Conference
    • Oct 07, 2011: Novel Technique Uses RNA Interference To Block Inflammation
    • Aug 16, 2010: MMV Becomes First PDP To Make Its IP Freely Available For Neglected Diseases Research
    • Jun 28, 2010: Alnylam Scientists And Collaborators Publish Research In Nature Chemical Biology On Novel Mechanism For Regulation Of Gene Expression With Anti-Gene RNAs
    • Jan 20, 2010: GSK And Alnylam Select BIO Ventures For Global Health To Administer Intellectual Property Pool
    • Sep 09, 2009: EPO Issues Notification Of Intent To Grant Patent In Kreutzer-Limmer III Patent Series
    • Aug 11, 2009: Alnylam, Regulus Receives Notice Of Allowance From USPTO
    • Jul 08, 2009: Alnylam Joins GSK In Patent Pool For Neglected Tropical Diseases
    • Product News
    • Dec 23, 2008: Alnylam Advances Rnai Therapeutics Pipeline And Files Companys First Systemic Delivery Ind
    • Dec 19, 2008: Alnylam Publishes Pre-Clinical Research On Direct Cns Delivery Of Rnai Therapeutics
    • Dec 19, 2005: Alnylam Initiates Second Phase I Clinical Study Of Aln-Rsv01, An Rnai Therapeutic For The Treatment Of Respiratory Syncytial Virus (Rsv) Infection; Both U.S. And European Trials Now Underway
    • Dec 16, 2010: Alnylam Presents New Data On Delivery Of RNAi Therapeutics And Human Translation
    • Dec 15, 2009: Isis, Alnylam Receive Notice of Allowance For New US Patent
    • Dec 13, 2007: Alnylam Reports Continued Progress In Clinical Development Of Aln-Rsv01 For The Treatment Of Respiratory Syncytial Virus (Rsv) Infection
    • Dec 08, 2008: Alnylam Strengthens Intellectual Property Estate Through Acquisition Of Nucleonics Patent Assets
    • Dec 07, 2005: Alnylam Initiates Phase I Clinical Study Of Aln-Rsv01, An Rnai Therapeutic For The Treatment Of Respiratory Syncytial Virus (Rsv) Infection Treatment Of Respiratory Syncytial Virus (Rsv) Infection
    • Dec 05, 2006: Alnylam Advances A Systemically Delivered Rnai Therapeutic Targeting Pcsk9 For The Treatment Of Hypercholesterolemia As New Development Program
    • Nov 28, 2006: Alnylam Initiates Clinical Program To Evaluate Anti-Viral Activity For Aln-Rsv01, An Rnai Therapeutic For The Treatment Of Respiratory Syncytial Virus (Rsv) Infection
    • Nov 27, 2006: Isis And Alnylam Announce Issued U.S. Patent Broadly Covering Chemical Modifications Of Oligonucleotide Therapeutics
    • Nov 20, 2008: Alnylam Presents Pre-Clinical Data From Ttr Amyloidosis Development Program
    • Nov 18, 2009: Alnylam Presents New Pre-clinical Data On Anti-Tumor Drug
    • Nov 04, 2008: Alnylam And Collaborators Publish New Pre-Clinical Research On Therapeutic Silencing Of Key Gene Implicated In Parkinsons Disease
    • Nov 01, 2005: Alnylam Submits Ind Apllication For Aln-Rsvoi, An Rnai Therapeutic For The Treatment Of Respiratory Syncytial Virus (Rsv) Infection; Represents First Rnai Therapeutic For Viral Infectious Diseases And Alnylams Lead Clinical-Stage Program
    • Oct 29, 2010: Alnylam Scientists To Present New Data On RNAi Therapeutics At Annual Meeting Of American Association For Study Of Liver Diseases
    • Oct 11, 2011: Alnylam And Collaborators Publish New Pre-clinical Data On Delivery Of RNAi Therapeutics To Key Cell Types Regulating Immune And Inflammatory Diseases
    • Oct 11, 2006: Alnylam Initiates Phase I Clinical Study Of Inhaled Formulation Of Aln-Rsv01, An Rnai Therapeutic For The Treatment Of Respiratory Syncytial Virus (Rsv) Infection
    • Oct 03, 2007: Alnylam Grants Genedesign License To Kreutzer-Limmer Patents For The Rna Interference (Rnai) Research Products Market
    • Sep 22, 2003: Alnylam Licenses Intellectual Property In Rna Interference To Further Strengthen Patent Portfolio
    • Sep 21, 2005: Alnylam Grants Qiagen License To Kreutzer-Limmer Patents In The Research Products Market
    • Sep 20, 2005: Alnylam Accelerates Rsv Infection Program And Provides Update On Amd Program; Progress With Rsv Program Supports Ind Filing By Year End
    • Sep 17, 2009: Regulus, Alnylam, And Isis Announce First MicroRNA Patent Grant In Japan From Tuschl III Patent Series
    • Sep 13, 2005: Alnylam And Isis License Intellectual Property For Microrna Gene Involved In Hepatitis C Virus Infection; Rolvirus Infection; Role Of Microrna-122 In Science
    • Sep 12, 2011: Alnylam Scientists And Collaborators Report Significant New Advances In Delivery Of RNAi Therapeutics At 2011 Oligonucleotides Therapeutics Society Meeting
    • Sep 07, 2007: Isis And Alnylam Launch Regulus Therapeutics, A Joint Venture To Discover, Develop, And Commercialize Microrna Therapeutics
    • Sep 04, 2008: Isis Receives Notices Of Allowance That Significantly Expand The Scope Of Key Rna Therapeutic Patents
    • Aug 24, 2010: Alnylam Scientists Present New Data On RNAi Therapeutics At American Chemical Society 2010 National Meeting
    • Aug 23, 2010: Alnylam And Collaborators Publish New Preclinical Research On Therapeutic Silencing Of Parkinson's Disease Gene
    • Aug 12, 2008: Alnylam And Collaborators Publish New Pre-Clinical Research On Rnai-Mediated Silencing Of Pcsk9, A Genetically Validated Regulator Of Ldl Metabolism
    • Aug 11, 2009: Alnylam And Regulus Receive Notice Of Allowance From US Patent And Trademark Office For New Patent Covering microRNA Therapeutics
    • Aug 09, 2010: Alnylam Scientists And Collaborators Report Significant New Advances In RNAi Delivery
    • Aug 09, 2005: Alnylam Receives Allowance For Board New European Patent Covering Rnai Therapeutics; New "kreutzer-Limmer Ii Patent Covers Rnai Therapeutics Towards Over 125 Disease Targets
    • Aug 04, 2008: Alnylam Consolidates Intellectual Property For Rna Activation (Rnaa), A New Biological Discovery For Activation Of Gene Expression
    • Aug 03, 2004: Hybridon Licenses Key Vegf Patents To Alnylam For Treatment Of Ocular Diseases With Rnai Therapeutics
    • Aug 01, 2007: Alnylam Receives Allowance From European Patent Office For Tuschl Ii Patent, Exclusively Licensed From Max Planck Society
    • Jul 29, 2003: Alnylam Announces In-Licensing Of Key Patents To Further Consolidate Intellectual Property In Rna Interference
    • Jul 25, 2011: Alnylam And MIT Collaborators Discover New Core-Shell Nanoparticles For Systemic Delivery Of RNAi Therapeutics
    • Jul 25, 2005: Alnylam Grants Mwg Biotech License To Fundamental Rnai Patents For Applications In The Research Products Market
    • Jul 20, 2009: Alnylam And Cubist Announce Complete Data From Phase Ii Study Of Aln-Rsv01 In Lung Transplant Patients Naturally Infected With Respiratory Syncytial Virus
    • Jul 19, 2007: Alnylam Grants Hayashi Kasei License To Kreutzer-Limmer Patents For The Rna Interference (Rnai) Research Products Market
    • Jul 19, 2005: Sigma-Aldrich Licenses Fundamental Rnai Patent Estate From Alnylam
    • Jul 18, 2006: Alnylam Receives New Issued U.S. Patent Broadly Covering Small Interfering Rnas And Strengthens Leadership In Intellectual Property For Rnai Therapeutics
    • Jul 17, 2006: Alnylam And Inex Accelerate Collaboration On Systemic Delivery Of Rnai Therapeutics; Positive Results For Systemic Rnai Support Advancement To Next Phase Of Collaboration
    • Jul 15, 2009: Alnylams Kreutzer-Limmer Ii Patent Upheld In European Opposition Proceedings
    • Jul 12, 2005: Alnylam Grants Eurogentec License To Fundamental Rnai Patents In The Research Products Market
    • Jul 10, 2008: Alnylam Provides Update On "glover" Patent
    • Jul 08, 2009: Alnylam Joins Gsk In Donating Intellectual Property To Patent Pool For Neglected Tropical Diseases
    • Jul 07, 2010: Alnylam Initiates Dosing In Phase I Clinical Study Of Aln-Ttr01 In Patients With Transthyretin-Mediated Amyloidosis (Attr)
    • Jun 29, 2010: Alnylam Obtains Approvals To Initiate Phase I Study With Aln-Ttr01 In Patients With Ttr-Mediated Amyloidosis (Attr)
    • Jun 26, 2009: Alnylam Joins Max Planck In Legal Action Toward Whitehead Institute
    • Jun 26, 2007: Alnylam Initiates Phase Ii Clinical Trial To Evaluate Safety And Anti-Viral Efficacy Of Aln-Rsv01 In The Treatment Of Respiratory Syncytial Virus (Rsv) Infection
    • Jun 22, 2006: Alnylam Reports Positive Outcome In European Opposition Proceedings On Kreutzer-Limmer I Patent; Amended Claims Broadly Cover Sirnas With Key Features Critical For Rnai Therapeutics
    • Jun 19, 2011: Alnylam Scientists And Collaborators Publish New Article In Nature Describing Discovery Of Central Gene In Mitochondrial Physiology
    • Jun 19, 2008: Aln-Rsv01, Alnylams Lead Rnai Therapeutic, Is In Phase Ii Clinical Development For Treatment Of Respiratory Syncytial Virus (Rsv) Infection -
    • Jun 18, 2009: Alnylam And Collaborators Present New Pre-Clinical Research Findings On Rnai Therapeutics Targeting Pcsk9, A Genetically Validated Regulator Of Ldl Metabolism
    • Jun 17, 2010: Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office For New Patent Broadly Covering Rnai Therapeutics That Target Mutated Genes
    • Jun 17, 2010: Alnylam Receives USPTO's Notice Of Allowance For New Patent Covering RNAi Therapeutics That Target Mutated Genes
    • Jun 16, 2005: Alnylam Amends Agreements With Max Planck Society And Reinforces Exclusive License To Key Fundamental Patent For Rnai; Amended Agreement Increases Operating Flexibility At Alnylam Europe Ag
    • Jun 08, 2009: Alnylam And Cubist Report Preliminary Data From Phase Ii Study Of Aln-Rsv01 In Lung Transplant Patients Naturally Infected With Respiratory Syncytial Virus
    • Jun 08, 2009: Alnylam To Webcast Conference Call To Discuss Preliminary Data From Phase Ii Study Of Aln-Rsv01
    • Jun 07, 2010: Alnylam Presents Preliminary Phase I Data At American Society Of Clinical Oncology (Asco) Meeting For Aln-Vsp, An Rnai Therapeutic For The Treatment Of Liver Cancers
    • Jun 06, 2006: Alnylam Receives Issued U.S. Patent Broadly Covering Rnai Therapeutics; Tuschl Ii Patent Covers Methods Of Making Small Interfering Rnas To Silence Any And All Disease Targets
    • Jun 01, 2010: Alnylam And Collaborators Discover New Class Of Small Viral RNAs In Flu
    • May 24, 2006: Alnylam Grants Bioneer License To Kreutzer-Limmer Patents For The Rna Interference (Rnai) Research Products Market
    • May 11, 2010: Alnylam Announces Publication Of Pre-Clinical Research On Key Mechanism For Delivery Of RNAi Therapeutics With Lipid Nanoparticles
    • May 07, 2007: Alnylam Reports Results Of Human Experimental Infection Model With Respiratory Syncytial Virus
    • May 06, 2008: Regulus Therapeutics Exclusively Licenses Intellectual Property From Stanford University Relating To Microrna Antagonists To Treat Inflammatory Diseases
    • May 03, 2010: Alnylam Receives Intent To Grant By European Patent Office For New Patent Broadly Covering RNAi Therapeutics
    • Apr 30, 2006: Alnylam Reports Phase I Clinical Safety Data For Aln-Rsv01, An Rnai Therapeutic For The Treatment Of Rsv Infection; Results Reported At The 2006 Pediatric Academic Societies Annual Meeting
    • Apr 28, 2010: Alnylam Biotherapeutics Presents New Results On Use Of RNAi Technologies For Biotherapeutics Manufacturing
    • Apr 27, 2009: Alnylam Granted New Fundamental Patent In China Broadly Covering Rnai Therapeutics
    • Apr 25, 2006: Therapeutic For The Treatment Of Rsv, At The 2006 Pediatric Academic Societies Annual Meeting
    • Apr 21, 2009: Alnylam Announces Allowance In Europe Of New Fundamental Patent Broadly Covering Rnai Therapeutics
    • Apr 20, 2009: Alnylam Announces Allowance In Europe Of New Fundamental Patent Broadly Covering RNAi Therapeutics
    • Apr 17, 2007: Alnylam Announces Advancement Of A New Rnai Therapeutic Development Program For The Treatment Of Liver Cancer
    • Apr 12, 2005: Alnylam And Benitec Form Alliance On Fundamental Intellectual Property For Rnai Therapeutics
    • Apr 09, 2008: Lung Transplant Patients Naturally Infected With Respiratory Syncytial Virus (Rsv) Infection
    • Apr 07, 2010: Alnylam Announces Grant Of New US Patent Broadly Covering RNAi Therapeutics
    • Mar 31, 2010: Alnylam Announces Additional Grant Of Tuschl II Patent In Japan
    • Mar 29, 2007: Alnylam Grants Bio-Rad License To Kreutzer-Limmer Patents For The Rna Interference (Rnai) Research Products Market
    • Mar 20, 2008: Alnylam Grants Shanghai Genepharma License To Kreutzer-Limmer Patents For The Rna Interference (Rnai) Research Products Market
    • Mar 07, 2007: Inex And Alnylam Announce Allowance Of New U.S. Patent Covering Delivery Of Rnai Therapeutics
    • Mar 01, 2007: Alnylam And Isis Announce Allowance Of First U.S. Patent Covering Human Micrornas
    • Feb 29, 2008: Alnylam Achieves First Human Proof Of Concept For An Rnai Therapeutic With Gemini Study
    • Feb 28, 2006: Alnylam Grants Integrated Dna Technologies License To Kreutzer-Limmer Patents For The Rna Interference Research Products Market; Leading Provider Of Custom Nucleic Acids Gains Accesss To First Issued Rnai Research Patents
    • Feb 25, 2008: Alnylam To Webcast Conference Call To Discuss Phase Ii Gemini Data For Aln-Rsv01, An Rnai Therapeutic For The Treatment Of Respiratory Syncytical Virus(Rsv) Infection
    • Feb 25, 2005: Alnylam Data Presented On Rnai Therapeutics For Age-Related Macular Degeneration; Preclinical Data Reported At The Macula Society Meeting
    • Feb 12, 2009: Alnylam And Collaborators Present Data From Multiple Pre-Clinical And Clinical Programs At Rnai Keystone Symposium
    • Feb 11, 2009: Alnylam And Collaborators Publish New Pre-Clinical Research Demonstrating In Vivo Efficacy Of Systemically Delivered Rnai Therapeutics In Ovarian Cancer
    • Feb 11, 2009: Alnylam And Collaborators Publish New PreClinical Research Demonstrating In Vivo Efficacy Of Systemically Delivered RNAi Therapeutics In Ovarian Cancer
    • Feb 10, 2009: Alnylam Receives New Patent Covering RNAi Therapeutics
    • Feb 10, 2009: Alnylam Receives Grant Of New Patent Broadly Covering Rnai Therapeutics
    • Feb 08, 2010: Alnylam Receives Notice Of Allowance From US Patent And Trademark Office For New Patent Broadly Covering RNAi Therapeutics
    • Feb 07, 2008: Alnylam Reports Pre-Clinical Progress With Rnai Therapeutics In Neurological Disease
    • Jan 27, 2004: Alnylam Grants Rnax License To Key Patent In Rna Interference
    • Jan 25, 2010: Regulus, Alnylam and Isis Announce US Allowance Of Tuschl III Patent Application Covering miR-21
    • Jan 24, 2006: Alnylam Announces Allowance Of Additional U.S. Patent Broadly Covering Rnai Therapeutics; New Allowance Strengthens Alnylams Intellectual Property Position In The Field Of Rnai
    • Jan 23, 2009: Alnylam Receives Clearance From Fda To Initiate Phase I Study With Aln-Vsp For The Treatment Of Liver Cancers
    • Jan 23, 2008: Alnylam Reports Positive Phase Ii Data For Aln-Rsv01, An Rnai Therapeutic For The Treatment Of Respiratory Syncytial Virus (Rsv) Infection
    • Jan 22, 2004: Alnylam Licenses Intellectual Property From Cold Spring Harbor Laboratory
    • Jan 20, 2009: Alnylam Provides Update On Kreutzer-Limmer Patent Family
    • Jan 19, 2010: Alnylam And Collaborators Discover Additional Class Of Lipid Nanoparticles
    • Jan 17, 2006: Alnylam Announces Allowance Of U.S. Patent Broadly Covering Rnai Therapeutics; Patent Rights For Tuschl Ii Are Held Exclusively By Alnylam For Development And Commercialization Of Rnai Therapeutics
    • Jan 13, 2004: Alnylam And Cenix Bioscience Enter Into Research Alliance And Licensing Agreement In Rna Interference
    • Jan 13, 2004: Alnylam Licenses Fundamental Patent In Rna Interference To Cell Signaling Technology
    • Jan 13, 2004: Alnylam Licenses Fundamental Patent In Rna Interference To Invitrogen
    • Jan 10, 2011: Alnylam's Phase I Clinical Data For ALN-VSP Validates LNP technology, Tekmira Says
    • Jan 10, 2005: Alnylam Scientists Report Progress On Rsv Program And Systemic Rnai Therapeutics
    • Jan 09, 2009: Alnylam And Cubist Form Strategic Collaboration To Develop And Commercialize Rnai Therapeutics Targeting Respiratory Syncytial Virus (Rsv) Infection
    • Jan 08, 2010: Alnylam And Collaborators Discover Key Mechanism For Delivery Of RNAi Therapeutics
    • Jan 05, 2006: Alnylam Grants Dharmacon License To Kreutzer-Limmer Patents For The Rna Interference Research Products Market; Leading Provider Of Rnai Research Tools Gaiin Access To First Issued Rnai Research Patents In Europe
    • Jan 03, 2008: Alnylam Announces Continued Progress On Development Of Its Intellectual Property Estate Covering Rnai Therapeutics
    • Product Approvals
    • Jun 29, 2010: Alnylam Obtains Approval To Initiate Phase I Study With ALN-TTR01 In Patients With TTR-Mediated Amyloidosis
    • Clinical Trials
    • Mar 31, 2011: Alnylam Completes Enrollment In ALN-VSP Phase I Clinical Trial
    • Jan 04, 2011: Alnylam Reports Positive Data From ALN-VSP Phase I Liver Cancer Trial
    • Nov 10, 2010: Alnylam Presents Additional Interim Phase I Data For ALN-VSP For Treatment Of Liver Cancer
    • Sep 29, 2010: Alnylam Announces Publication Of Phase IIa Study Results Of ALN-RSV01 In Treatment Of RSV Infection In Lung Transplant Patients
    • Jul 07, 2010: Alnylam Doses ATTR Patients In Phase I Clinical Study Of ALN-TTR01
    • Jun 07, 2010: Alnylam Presents Preliminary Phase I Data At ASCO Meeting For ALN-VSP
    • Apr 20, 2010: Alnylam And Collaborators Present New Pre-Clinical Data From ALN-TTR01 Program
    • Feb 22, 2010: Alnylam Initiates Phase IIb Clinical Trial Of ALN-RSV01 In Adult Lung Transplant Patients Infected with RSV Infection
    • Sep 15, 2009: Alnylam And Medtronic Presents New Late-Stage Pre-clinical Data On ALN-HTT For The Treatment Of Huntington's Disease.
    • Jul 20, 2009: Alnylam And Cubist Reports Complete Data From Phase II Study In Respiratory Syncytial Virus
    • Jun 18, 2009: Alnylam And Collaborators Presents New Pre-Clinical Research Findings On RNAi Therapeutics Targeting PCSK9
    • Jun 08, 2009: Alnylam And Cubist Report Preliminary Data From Phase II Study Of ALN-RSV01
    • Apr 03, 2009: Alnylam Initiates Phase I Clinical Study of ALN-VSP in Patients with Liver Cancer
    • Aug 12, 2008: Alnylam And Collaborators Publish New Pre-Clinical Research On RNAi-Mediated Silencing Of PCSK9
    • Apr 09, 2008: Alnylam Initiates Phase II Trial Of ALN-RSV01 In Adult Lung Transplant Patients Naturally Infected With Respiratory Syncytial Virus (RSV) Infection
    • Dec 13, 2007: Alnylam Reports Phase I Clinical Safety Results With Inhalation Dosing Of ALN-RSV01
    • Oct 17, 2007: Alnylam and Collaborators Publish New Pre-clinical Results on RNAi Therapeutics for the Treatment of Huntington's Disease
    • Nov 06, 2006: Alnylam And Yale University Scientists Demonstrate Therapeutic Silencing Of Disease Target Associated With Acute Lung Injury Using RNAi
    • Oct 11, 2006: Alnylam Initiates Phase I Clinical Study Of Inhaled Formulation Of ALN-RSV01
    • May 23, 2006: Alnylam And Collaborators Present Pre-Clinical Data For RNAi Therapeutics For The Treatment Of Respiratory Diseases
    • May 23, 2006: Alnylam and Collaborators Present Pre-Clinical Data For RNAi Therapeutics For The Treatment Of Respiratory Diseases Including Pandemic Influenza
    • Mar 18, 2005: In Vivo Efficacy Data Presented From Alnylam RSV Program At The American Academy Of Allergy, Asthma And Immunology Meeting
  • Appendix
  • Methodology
  • About GlobalData
  • Contact Us
  • Disclaimer 246
  • List of Tables
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Key Facts, 2010
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare Deals By Type, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Deals By Therapy Area, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Medical Devices Deals, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Therapy Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Partnerships, Deals By Phase Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Licensing Deals, Deals By Therapy Area Vs Deal Value Vs Upfront Payment, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals Summary, 2006 to YTD 2012
    • Alnylam Acquires RNAi Therapeutics Assets From Nucleonics
    • Regulus Therapeutics Secures $20 Million In Series A Preferred Equity Financing
    • Molecular Templates Enters Into Research Collaboration With Alnylam Pharmaceuticals
    • Precision NanoSystems Enters Into Delivery Collaboration With Alnylam
    • AlCana Extends Co-Development Agreement With UBC And Alnylam
    • Alnylam And Medtronic Form Collaboration With CHDI Foundation
    • Alnylam Pharmaceuticals Enters Into Agreement With Tekmira Pharmaceuticals
    • Novartis Extends Agreement With Alnylam Pharmaceuticals
    • Cubist Pharmaceuticals Enters Into Co-Development Agreement With Alnylam
    • Alnylam Enters Into Research Agreement With Max Planck Institute
    • Novartis Extends Co-Development Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals And Kyowa Hakko Form Alliance
    • Alnylam Pharmaceuticals Forms Joint Venture With Isis Pharmaceuticals
    • Alnylam Pharmaceuticals Amends Agreement With Medtronic
    • Biogen Idec Enters Into Agreement With Alnylam
    • Tekmira Amends Research Collaboration With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals Amends Its Collaboration Agreement With Merck
    • Alnylam Pharmaceuticals Enters Into Collaboration Agreement With USAMRIID
    • Alnylam Pharmaceuticals Enters Into Research Agreement With Inex Pharmaceuticals
    • Alnylam Enters Into Co-Development Agreement With Novartis
    • Bio-Rad Laboratories Enters Into An Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Inex Pharmaceuticals
    • Alnylam Enters Into Licensing Agreement With Dharmacon
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Arrowhead Research
    • Arrowhead Research Enters Into Licensing Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Option Licensing Agreement With Sylentis
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With GlaxoSmithKline
    • Tekmira Pharmaceuticals Enters Into Licensing Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Tekmira Pharmaceutical
    • The University of Queensland Enters Into Licensing Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Mount Sinai School
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With University of Queensland
    • Roche Expands Licensing Agreement With Alnylam
    • Alnylam Enters Into License Agreement With Koken
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Isis Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Calando Pharmaceuticals
    • Takeda Pharmaceutical Enters Into Collaboration Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals And Tekmira Pharmaceutical Enter Into Licensing Agreement
    • Alnylam Enters Into Agreement With Shanghai GenePharma
    • Alnylam Pharmaceuticals Enter Into Licensing Agreement With GeneDesign
    • Roche Enters Into Licensing Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement with Hayashi Kasei
    • Alnylam Enters Into Licensing Agreement With Inex Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Quark Pharmaceuticals
    • Alnylam Enters Into Agreement With Calando
    • Alnylam Enters Into Agreement With Bioneer
    • Alnylam Enters Into Agreement With Immune Disease Institute
    • Alnylam Enters Into Agreements With Massachusetts Institute of Technology
    • Gen-Probe Enters Into Licensing Agreement With Alnylam Pharmaceuticals
    • Alnylam Pharmaceuticals Enters Into Licensing Agreement With Integrated DNA Technologies
    • Alnylam Pharmaceuticals Files Registration Statement For Public Offering Of Securities For $150 Million
    • Alnylam Completes Private Placement Of $1 Million With Novartis
    • Tekmira Completes Private Placement Of $5 Million With Alnylam
    • Alnylam Pharmaceuticals Completes Private Placement Of $5 Million
    • Alnylam Pharmaceuticals Completes Public Offering Of $103 Million
    • Alnylam Completes Public Offering Of $67 Million
    • Alnylam Pharmaceuticals, Inc, Key Competitors
    • Alnylam Pharmaceuticals, Inc, Key Employees
    • Alnylam Pharmaceuticals, Inc, Subsidiaries 93
  • List of Figures
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Licensing Deals by Year, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Region, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2006 to YTD 2012
    • Alnylam Pharmaceuticals, Inc, Pharmaceuticals & Healthcare, Medical Devices Deals, 2006 to YTD 2012
+44 20 8816 8548

Ask a question about Alnylam Pharmaceuticals, Inc (ALNY) - Pharmaceuticals & Healthcare

Enter the characters you see in the picture below
Captcha